Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management
Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present h...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Humana Press
2000
|
| Schriftenreihe: | Current Clinical Oncology
|
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Currently the functions of the VHL protein are being investigated, and the biology of clear cell carcinoma of the kidney is under study. Additionally, papillary carcinomas of the kidney appear to express different molecular defects, and these are now being unraveled |
| Beschreibung: | 1 Online-Ressource (XI, 434 p. 148 illus) |
| ISBN: | 9781592592296 |
| DOI: | 10.1007/978-1-59259-229-6 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046145250 | ||
| 003 | DE-604 | ||
| 005 | 20210610 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2000 |||| o||u| ||||||eng d | ||
| 020 | |a 9781592592296 |9 978-1-59259-229-6 | ||
| 024 | 7 | |a 10.1007/978-1-59259-229-6 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-59259-229-6 | ||
| 035 | |a (OCoLC)1119066772 | ||
| 035 | |a (DE-599)BVBBV046145250 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 084 | |a XH 7850 |0 (DE-625)152946:13129 |2 rvk | ||
| 245 | 1 | 0 | |a Renal Cell Carcinoma |b Molecular Biology, Immunology, and Clinical Management |c edited by Ronald M. Bukowski, Andrew C. Novick |
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 2000 | |
| 300 | |a 1 Online-Ressource (XI, 434 p. 148 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Current Clinical Oncology | |
| 520 | |a Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Currently the functions of the VHL protein are being investigated, and the biology of clear cell carcinoma of the kidney is under study. Additionally, papillary carcinomas of the kidney appear to express different molecular defects, and these are now being unraveled | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Hypernephrom |0 (DE-588)4161076-3 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Hypernephrom |0 (DE-588)4161076-3 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Bukowski, Ronald M. |4 edt | |
| 700 | 1 | |a Novick, Andrew C. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781475764017 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780896037816 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781475764000 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-59259-229-6 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525435 | ||
| 966 | e | |u https://doi.org/10.1007/978-1-59259-229-6 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180481683488768 |
|---|---|
| any_adam_object | |
| author2 | Bukowski, Ronald M. Novick, Andrew C. |
| author2_role | edt edt |
| author2_variant | r m b rm rmb a c n ac acn |
| author_facet | Bukowski, Ronald M. Novick, Andrew C. |
| building | Verbundindex |
| bvnumber | BV046145250 |
| classification_rvk | XH 7850 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-59259-229-6 (OCoLC)1119066772 (DE-599)BVBBV046145250 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-59259-229-6 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03206nmm a2200481zc 4500</leader><controlfield tag="001">BV046145250</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20210610 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2000 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781592592296</subfield><subfield code="9">978-1-59259-229-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-59259-229-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-59259-229-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119066772</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145250</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 7850</subfield><subfield code="0">(DE-625)152946:13129</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Renal Cell Carcinoma</subfield><subfield code="b">Molecular Biology, Immunology, and Clinical Management</subfield><subfield code="c">edited by Ronald M. Bukowski, Andrew C. Novick</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XI, 434 p. 148 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Current Clinical Oncology</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Currently the functions of the VHL protein are being investigated, and the biology of clear cell carcinoma of the kidney is under study. Additionally, papillary carcinomas of the kidney appear to express different molecular defects, and these are now being unraveled</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hypernephrom</subfield><subfield code="0">(DE-588)4161076-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Hypernephrom</subfield><subfield code="0">(DE-588)4161076-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bukowski, Ronald M.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Novick, Andrew C.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781475764017</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780896037816</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781475764000</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-59259-229-6</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525435</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-59259-229-6</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV046145250 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:27Z |
| institution | BVB |
| isbn | 9781592592296 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525435 |
| oclc_num | 1119066772 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (XI, 434 p. 148 illus) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | Humana Press |
| record_format | marc |
| series2 | Current Clinical Oncology |
| spelling | Renal Cell Carcinoma Molecular Biology, Immunology, and Clinical Management edited by Ronald M. Bukowski, Andrew C. Novick Totowa, NJ Humana Press 2000 1 Online-Ressource (XI, 434 p. 148 illus) txt rdacontent c rdamedia cr rdacarrier Current Clinical Oncology Renal cell carcinoma represents a heterogeneous group of tumors, the most common of which is clear cell adenocarcinoma. The annual incidence of this tumor appears to be rising and approximately 12,000 individuals die from this cancer annually in the United States. One third of patients who present have metastatic disease at the time of diagnosis, and another 40% who undergo nephrectomy will ultimately develop this complication. Over the past 10 years, a significant amount of new information concerning the epidemiology, mole- lar and immunologic characteristics, and therapy for patients with these tumors has appeared. The recognition that inherited forms of renal cancer exist, and that chromosomal abn- malities can be identified in these tumors, suggested a genetic basis for renal cell carcinoma. The familial cancer syndrome, Von Hippel Lindau disease, provided the setting in which the genetic abnormalites associated with the development of renal cancer were first described. Abnormalities of the VHL gene have also been detected in sporadic clear cell carcinoma, and it has now been recognized that approximately 80 % of these tumors will demonstrate ch- acteristic alterations. Currently the functions of the VHL protein are being investigated, and the biology of clear cell carcinoma of the kidney is under study. Additionally, papillary carcinomas of the kidney appear to express different molecular defects, and these are now being unraveled Oncology Oncology Hypernephrom (DE-588)4161076-3 gnd rswk-swf Hypernephrom (DE-588)4161076-3 s DE-604 Bukowski, Ronald M. edt Novick, Andrew C. edt Erscheint auch als Druck-Ausgabe 9781475764017 Erscheint auch als Druck-Ausgabe 9780896037816 Erscheint auch als Druck-Ausgabe 9781475764000 https://doi.org/10.1007/978-1-59259-229-6 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Renal Cell Carcinoma Molecular Biology, Immunology, and Clinical Management Oncology Oncology Hypernephrom (DE-588)4161076-3 gnd |
| subject_GND | (DE-588)4161076-3 |
| title | Renal Cell Carcinoma Molecular Biology, Immunology, and Clinical Management |
| title_auth | Renal Cell Carcinoma Molecular Biology, Immunology, and Clinical Management |
| title_exact_search | Renal Cell Carcinoma Molecular Biology, Immunology, and Clinical Management |
| title_full | Renal Cell Carcinoma Molecular Biology, Immunology, and Clinical Management edited by Ronald M. Bukowski, Andrew C. Novick |
| title_fullStr | Renal Cell Carcinoma Molecular Biology, Immunology, and Clinical Management edited by Ronald M. Bukowski, Andrew C. Novick |
| title_full_unstemmed | Renal Cell Carcinoma Molecular Biology, Immunology, and Clinical Management edited by Ronald M. Bukowski, Andrew C. Novick |
| title_short | Renal Cell Carcinoma |
| title_sort | renal cell carcinoma molecular biology immunology and clinical management |
| title_sub | Molecular Biology, Immunology, and Clinical Management |
| topic | Oncology Oncology Hypernephrom (DE-588)4161076-3 gnd |
| topic_facet | Oncology Oncology Hypernephrom |
| url | https://doi.org/10.1007/978-1-59259-229-6 |
| work_keys_str_mv | AT bukowskironaldm renalcellcarcinomamolecularbiologyimmunologyandclinicalmanagement AT novickandrewc renalcellcarcinomamolecularbiologyimmunologyandclinicalmanagement |